Real-word elegibiliy and tolerability of vericiguat in HFrEF: data from a multicenter registry

9 May 2026 (08:00 - 12:45)

Organised by:

Sign in to view the resources

About the speaker

Associate Professor Savina Nodari

University of Brescia, Brescia (Italy)

5 More presentations in this session

Presentation thumbnail

Effect of GDMT optimization on KDIGO risk categories in HFrEF

Doctor N. Panagiotides (Vienna, AT)

Presentation thumbnail

Treatment patterns of heart failure patients with reduced or mildly reduced ejection fraction on dapagliflozin: baseline data from the 3rd interim analysis of two EVOLUTION-HF DEallEF study cohorts

Professor M. Paul (Muenster, DE)

Presentation thumbnail

Intravenous iron therapy in heart failure with preserved ejection fraction: a systematic review and meta-analysis

Doctor R. Ali (Pembroke Pines, US)

Presentation thumbnail

Comparison of the 2016 and 2025 ASE/EACVI Guidelines on HFpEF

Miss W. Hu (Hangzhou, CN)

Presentation thumbnail

Bridging inequity in HFpEF care: pilot project experience informing the design and implementation of a multidisciplinary blueprint

Doctor M. Lee (Glasgow, GB)

Access the full session

Session thumbnail

Challenges and solutions in guideline-directed therapy in heart failure

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026

You may be interested in

Congress Presentation

Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.

Congress Presentation

Clinical characteristics and long-term prognosis of patients with heart failure with reduced, mildly reduced, and preserved left ventricular ejection fraction secondary to Chagas cardiomyopathy

Congress Session

Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources